About Us
“We are a biopharmaceutical company that believes connections unlock potential. We see it in the careers of our people, the evolution of our science, the therapies we are working to bring to market, and the impact we make by working together with patients and collaborators. Each is simply better as a result of the connections we make. By consistently tapping into the knowledge and experience of our patients, partners and colleagues, we elevate our thinking and unearth creative insights that propel ourselves and our science to new levels.
Building on these connections and our leadership in the field of cellular metabolism, we are pioneering therapies for rare diseases, with a near-term focus on developing therapies for hemolytic anemias. Our first rare disease therapy was approved by the FDA for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. The lead product candidate in our clinical portfolio, mitapivat, is being evaluated in late-stage clinical trials for thalassemia and sickle cell disease. We are also developing AG-946, a novel PK activator, for the potential treatment of hemolytic anemias and other indications. In addition to these lead programs, we foster a productive research engine and are advancing multiple novel, investigational therapies in preclinical development.”
To learn more visit us at www.agios.com.
